Department of Clinical Pharmacy, Deventer Teaching Hospital, Nico, Bolkesteinlaan 75, 7416 SE, Deventer, the Netherlands.
Unit of PharmacoTherapy, -Epidemiology &-Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, the Netherlands.
Eur J Clin Pharmacol. 2024 Mar;80(3):455-464. doi: 10.1007/s00228-023-03612-2. Epub 2024 Jan 13.
Oxycodone is known to have numerous drug-drug interactions (DDIs) that can potentially decrease efficacy or lead to adverse drug reactions (ADRs). However, there is limited research on the frequency of DDIs associated with oxycodone, which is important in optimising pharmacovigilance and the need for additional research on certain DDIs. In this study, the frequency of pharmacologically and clinically relevant DDI perpetrators was studied in patients with cancer.
This was a cross-sectional study using hospital pharmacy records of patients with cancer who were prescribed oxycodone between September 2021 and September 2022. Medication records of patients prescribed oxycodone during a period of ≥ 5 consecutive days (= oxycodone treatment episodes) were reviewed to identify the concomitant use of pharmacologically relevant perpetrators, based on reference sources (Lexicomp®, Micromedex®, the Dutch Kennisbank and the Dutch Commentaren Medicatiebewaking). The clinical relevance was examined by a clinical pharmacologist and a medical oncologist. Additionally, the frequency of double interactions-concomitant oxycodone use with two CYP3A4 and / or CYP2D6 perpetrators-was studied.
Overall, 254 oxycodone treatment episodes were included, of which 227 (89.4%) were found to contain at least one pharmacologically relevant DDI perpetrator. Of these, 210 (82.7%) were considered to be clinically relevant. A total of 80 different pharmacologically relevant perpetrators were identified, with 65 (81.3%) being considered clinically relevant. Double interactions were observed in 21 (8.3%) oxycodone treatment episodes.
A high frequency of pharmacologically and clinically relevant perpetrators of oxycodone was observed in our cohort. Moreover, a high number of double interactions involving oxycodone was registered. More intense monitoring of DDIs may be needed to improve medication safety of patients with cancer taking oxycodone.
已知羟考酮有许多药物-药物相互作用(DDI),可能会降低疗效或导致药物不良反应(ADR)。然而,关于与羟考酮相关的 DDI 的频率的研究有限,这对于优化药物警戒和对某些 DDI 进行额外研究很重要。在这项研究中,研究了癌症患者中与羟考酮相关的药理学和临床上相关的 DDI 肇事者的频率。
这是一项横断面研究,使用 2021 年 9 月至 2022 年 9 月期间开处羟考酮的癌症患者的医院药房记录。对连续 5 天以上(=羟考酮治疗期)开处羟考酮的患者的药物记录进行审查,以根据参考来源(Lexicomp®、Micromedex®、荷兰 Kennisbank 和荷兰 Commentaren Medicatiebewaking)识别药理学相关肇事者的同时使用情况。临床相关性由临床药理学家和肿瘤内科医生进行检查。此外,还研究了双重相互作用——同时使用两种 CYP3A4 和/或 CYP2D6 肇事者与羟考酮的同时使用频率。
总体而言,纳入了 254 个羟考酮治疗期,其中 227 个(89.4%)被发现含有至少一种药理学相关的 DDI 肇事者。其中,210 个(82.7%)被认为具有临床相关性。共鉴定出 80 种不同的药理学相关肇事者,其中 65 种(81.3%)被认为具有临床相关性。在 21 个(8.3%)羟考酮治疗期观察到双重相互作用。
在我们的队列中观察到羟考酮的药理学和临床上相关的肇事者的频率很高。此外,登记了大量涉及羟考酮的双重相互作用。可能需要更密切地监测 DDI,以提高服用羟考酮的癌症患者的药物安全性。